

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
RDID0013US

In Re Application Of: Ralf Zielenski, et al.

Serial No.
09/760,205

Filing Date
January 12, 2001

Examiner
To Be Assigned

Group Art Unit
To Be Assigned

Title: **STABILIZED COENZYME SOLUTIONS AND THEIR USE FOR DETERMINING DEHYDROGENANSE OR SUBSTRATES THEREOF**

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of _____ is attached.
- ☒ The Assistant Commissioner is hereby authorized to charge and credit Deposit Account No. 50-0877 as described below. A duplicate copy of this sheet is enclosed.
- ☐ Charge the amount of _____
- ☒ Credit any overpayment.
- ☒ Charge any additional fee required.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. _____) on _____
(Date)

Signature

Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail

I certify that this document and fee is being deposited on April 5, 2001 with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Signature of Person Mailing Correspondence

Leah Robison

Typed or Printed Name of Person Mailing Correspondence

*This certificate may only be used if paying by deposit account.

Marilyn Amick
Signature

Dated: *April 5, 2001*

Marilyn L. Amick, Reg. No. 30,444
Roche Diagnostics Corporation
9115 Hague Road
P.O. Box 50457
Indianapolis, IN 46250
Tel.: (317) 521-7561
Fax: (317) 521-2883

CC:

0320

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT

APR 11 2001

(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
RDID0013US

In Re Application Of: Ralf Zielenski, et al.

Serial No.

09/760,205

Filing Date

January 12, 2001

Examiner

To Be Assigned

Group Art Unit

To Be Assigned

Title: **STABILIZED COENZYME SOLUTIONS AND THEIR USE FOR DETERMINING DEHYDROGENASE OR SUBSTRATES THEREOF**

Address to:

Assistant Commissioner for Patents
Washington, D.C. 20231

37 CFR 1.97(b)

1. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application; within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; or before the mailing date of a first Office Action on the merits, whichever event occurs last.

37 CFR 1.97(c)

2. ☐ The Information Disclosure Statement submitted herewith is being filed after three months of the filing of a national application, or the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; or after the mailing date of a first Office Action on the merits, whichever occurred last but before the mailing date of either:

1. a Final Action under 37 CFR 1.113, or
2. a Notice of Allowance under 37 CFR 1.311,

whichever occurs first.

Also submitted herewith is:

- ☐ a certification as specified in 37 CFR 1.97(e);

OR

- ☐ the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under 37 CFR 1.97(c).